Clinical trials: Coagulation
X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
OBJECTIVES: I. Identify the molecular defects responsible for primary immunodeficiency disorders. II. Explore the mutations within each syndrome to better understand the genetics of these disorders. III.
- Conditions
- X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome, Wiskott-Aldrich Syndrome, Leukocyte Adhesion Deficiency Syndrome
- Trial name
- NCT00004341
- Where
- United States
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hemophilia B
Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
A long-term follow-up study to evaluate the safety, tolerability, and efficacy of DTX101 in adult males with moderate/severe to severe hemophilia B.
- Trial name
- NCT02971969
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Sepsis
Indicators of Inflammation and Coagulation in Sepsis
We will collect blood samples from patients with the diagnosis of sepsis and other ICU patients. We will describe the course of different mediator levels and organ injury markers and follow their progression throughout the course…
- Trial name
- NCT01128283
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Oklahoma
Inflammatory Bowel Diseases, Von Willebrand Diseases
Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease
The investigators are going to study von Willebrand antigen and activity levels in patients with inflammatory bowel disease. The study will be on 46 patients who were diagnosed with inflammatory bowel disease mainly ulcerative…
- Trial name
- NCT03715673
- Testing
- von willebrand antigen and activity
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Assiut University
Blood Coagulation Disorders
The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots
This is a randomized controlled trial to assess the effect of a levonorgesterel-releasing intrauterine device (LNG IUD, Mirena®) versus a copper IUD (Paraguard®) on coagulation parameters known to be associated with risk of…
- Trial name
- NCT00584610
- Testing
- Levonorgestrel-containing IUD (Mirena®), Copper-containing IUD (Paraguard®)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Glioma, Coagulopathy
Hemostasis Alterations in Neurosurgical Patients
Prospective, observational study aimed to investigate the specific hemostatic alterations in patients undergoing glial tumor resection.
- Conditions
- Glioma, Coagulopathy, Acquired Platelet Function Disorder, Thromboelastometry
- Trial name
- ABCD (NCT02652897)
- Testing
- Exposure to glioma resection surgery, Exposure to colon resection surgery
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Santiago R. Leal-Noval
Hemophilia A
Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A
Based on the successful pioneer work of Dr Nilsson and her colleagues in Sweden that started in the late 1950's, prophylaxis is recommend as the standard of care for boys with severe haemophilia by WHO and World Federation of…
- Trial name
- NCT02282410
- Testing
- ADVATE
- Volunteers
- 15 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Blood Coagulation Disorder
Biomarkers and Prediction of Tigecycline Induced Coagulation Dysfunction
This study is to screen out the biomarkers and establish the model to predict coagulation dysfunction induced tigecycline
- Trial name
- NCT05698160
- Volunteers
- 200 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).
- Trial name
- NCT00441090
- Testing
- Avatrombopag tablets
- Where
- 25 sites in United States
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Hemophilia A
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
The purpose of this study is to describe the pharmacokinetics (PK) of BAY94-9027(the test drug). Pharmacokinetics means that we will measure how well the study drug corrects the factor VIII levels in your blood and how long it…
- Trial name
- NCT01184820
- Testing
- BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222), BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Bayer
Skin Aging, Purpura
Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
The objectives of this study are to evaluate the safety and efficacy of 0.5% retinol (Vitamin A) versus it's vehicle cream in the treatment and prevention of skin aging and Bateman's Purpura (bruising).
- Trial name
- NCT00272610
- Testing
- 0.4% Retinol Cream
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan
Purpura, Thrombocytopenic, Idiopathic
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1 between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and six 3-week cycles of pulsed dexamethasone (0.6…
- Trial name
- EIS2002 (NCT02334813)
- Testing
- Prednisone, Dexamethasone
- Volunteers
- 26 people
- Sponsor
- University Hospital, Essen
Coagulation Defect; Bleeding
ROTEM Versus aPTT/PT in Pediatric Surgery
Hemocoagulation management in perioperative bleeding is nowadays based on standard coagulation testing: activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen, D-dimers, platelets.
- Trial name
- NCT03699813
- Testing
- Comparison of two approaches to bleeding management
- Volunteers
- 45 people
- Sponsor
- University Hospital, Motol
Congenital Bleeding Disorder, Haemophilia A
Survey Evaluating the Psychosocial Effects of Living With Haemophilia
This study is conducted in Africa, Asia, Europe, North America and South America. The purpose of the survey is to identify the key psychosocial issues affecting patients with haemophilia.
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B, Haemophilia A With Inhibitors
- Trial name
- HERO (NCT01322620)
- Testing
- No treatment given
- Where
- 3 sites in Canada, Spain and 1 more
- Volunteers
- 1,236 people
- Sponsor
- Novo Nordisk A/S
Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment
This multicenter, non-interventional, prospective study will collect information about activity status, bleeds, health-related quality of life (HRQoL), health status, and safety in participants with moderate or severe haemophilia…
- Conditions
- Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Haemophilia A
- Trial name
- POWER (NCT04165135)
- Testing
- Standard of Care for Haemophilia A
- Where
- 17 sites in Italy
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Hemophilia
A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors.
- Trial name
- NCT05027230
- Testing
- STSP-0601 for Injection
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Healthy Volunteers
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device
The goal in this study is to show that there are not significant differences in biologic activity of the study drug when administered using either the prefilled pen and prefilled syringe.
- Trial name
- NCT04832139
- Testing
- Marstacimab PFP, Marstacimab PFS
- Where
- Belgium
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Immune Thrombocytopenia, Pregnancy
Immune Thrombocytopenia in Pregnancy
The pregnancy may activate flares of certain autoimmune diseases such as lupus. The influence of pregnancy on the evolution of ITP was never studied while this pathology affects firstly women old enough to procreate.
- Trial name
- TIGRO (NCT02892630)
- Testing
- No intervention
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anticoagulation Reversal
Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
This study will evaluate the establishment of anticoagulation ("re-anticoagulation") of subjects with edoxaban following reversal by PER977 and will identify a dose regimen of PER977 that reverses the effects of edoxaban for up…
- Trial name
- NCT02207257
- Testing
- PER977, Edoxaban
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Wiskott-Aldrich Syndrome
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
A protocol named as "CIP-2015" for patients with Wiskott-Aldrich Syndrome may reduce the rate of GvHD. The details of the protocal followed with: 1. Conditioning regimen Busulfan 16 mg/kg in total, Fludarabine 160 mg/m2 in total.
- Trial name
- NCT03198195
- Testing
- cyclophosphamide
- Volunteers
- 5 people
- Sponsor
- Capital Research Institute of Pediatrics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.